Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role ofCDKN2Adeletions in theFGFR3pathway-Reference-Cited by-同舟云学术

Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role ofCDKN2Adeletions in theFGFR3pathway

Published:2016-10-28 Issue:2 Volume:70 Page:281-289
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Downes Michelle R¹²,Weening Berber¹³,van Rhijn Bas W G⁴,Have Cherry L¹,Treurniet Kilian M¹⁵,van der Kwast Theodorus H¹

Affiliation:

1. Department of Pathology; University Health Network and Princess Margaret Cancer Center; Toronto Canada

2. Department of Anatomic Pathology; Sunnybrook Health Sciences Centre; Toronto Canada

3. Department of Urology; Erasmus MC; Rotterdam the Netherlands

4. Department of Urology; Anthony Van Leeuwenhoek Hospital; Netherlands Cancer Institute; Amsterdam the Netherlands

5. Department of Radiology; Academic Medical Center; Amsterdam the Netherlands

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/his.13063/fullpdf

Reference23 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J. Clin.,2015

2. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials;Sylvester;Eur. Urol.,2006

3. Grade progression and regression in recurrent urothelial cancer;Borhan;J. Urol.,2003

4. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression;Samaratunga;Urology,2002

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Grade Heterogeneity in High-Grade Urothelial Carcinomas: Does It Have an Impact on the Survival of Patients With Intermediate/High-Risk Nonmuscle-Invasive Bladder Cancer Who Received Adequate Adjuvant Bacillus Calmette-Guérin Therapy?;Journal of Urology;2024-07

2. Editorial Comment on “Does Ta Low-grade Urothelial Carcinoma of the Bladder With Focal High-grade Features Carry Worse Prognosis? The Roswell Park Comprehensive Cancer Center Experience”;Urology;2024-07

3. Loss of MTAP Expression by Immunohistochemistry Is a Surrogate Marker for Homozygous 9p21.3 Deletion in Urothelial Carcinoma;Modern Pathology;2024-06

4. Preclinical models of bladder cancer: BBN and beyond;Nature Reviews Urology;2024-05-20

5. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2;American Journal of Surgical Pathology;2023-06-29